First results from Ebola vaccine trial show acceptable safety profile
- 29 January 2015
• GSK/NIH Ebola vaccine is 'well tolerated' and generates an immune response
• Larger trials in West Africa are needed to tell whether immune responses are large enough to protect against Ebola infection and disease
• Results from Oxford University and other safety trials will inform plans for larger trials
The first results from a trial of a candidate Ebola vaccine at Oxford University suggest the vaccine has an acceptable safety profile at the doses tested, and is able to generate an immune response.